 zidovudine therapy cost-effectiveness analysis Zidovudine ZDV first FDA-approved therapy HIV/AIDS dilemma policymaker hand ZDV life HIV-infected persons clear benefit hand lives infected individuals spread virus steep rise overall costs AIDS issue simple model ZDV therapy backdrop HIV transmission population active gay men basis fear dramatic increases incidence AIDS associated costs gay men due widespread ZDV distribution contrary analysis ZDV therapy cost-effective modest efforts behavior change prevention